These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 28521193)

  • 81. Effects of perfluorooctanoate and perfluorooctane sulfonate exposure on hepatoma Hep G2 cells.
    Hu XZ; Hu DC
    Arch Toxicol; 2009 Sep; 83(9):851-61. PubMed ID: 19468714
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Pharmacokinetic modeling of perfluorooctanoic acid during gestation and lactation in the mouse.
    Rodriguez CE; Setzer RW; Barton HA
    Reprod Toxicol; 2009 Jun; 27(3-4):373-386. PubMed ID: 19429408
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Integration of Toxicogenomics and Physiologically Based Pharmacokinetic Modeling in Human Health Risk Assessment of Perfluorooctane Sulfonate.
    Chen Q; Chou WC; Lin Z
    Environ Sci Technol; 2022 Mar; 56(6):3623-3633. PubMed ID: 35194992
    [TBL] [Abstract][Full Text] [Related]  

  • 84. The derivation of a Reference Dose (RfD) for perfluorooctane sulfonate (PFOS) based on immune suppression.
    Pachkowski B; Post GB; Stern AH
    Environ Res; 2019 Apr; 171():452-469. PubMed ID: 30739020
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Probabilistic human health risk assessment of perfluorooctane sulfonate (PFOS) by integrating in vitro, in vivo toxicity, and human epidemiological studies using a Bayesian-based dose-response assessment coupled with physiologically based pharmacokinetic (PBPK) modeling approach.
    Chou WC; Lin Z
    Environ Int; 2020 Apr; 137():105581. PubMed ID: 32087483
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Toxicity and toxicokinetics of perfluorooctanoic acid in humans and animals.
    Kudo N; Kawashima Y
    J Toxicol Sci; 2003 May; 28(2):49-57. PubMed ID: 12820537
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Plasma, liver, and kidney exposures in rats after oral doses of industrial chemicals predicted using physiologically based pharmacokinetic models: A case study of perfluorooctane sulfonic acid.
    Kamiya Y; Yanagi M; Hina S; Shigeta K; Miura T; Yamazaki H
    J Toxicol Sci; 2020; 45(12):763-767. PubMed ID: 33268676
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Neurobehavioral teratogenicity of perfluorinated alkyls in an avian model.
    Pinkas A; Slotkin TA; Brick-Turin Y; Van der Zee EA; Yanai J
    Neurotoxicol Teratol; 2010; 32(2):182-6. PubMed ID: 19945530
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Comment on: Dong et al. (2017) "Issues raised by the reference doses for perfluorooctonate sulfonate and perfluorooctanoic acid.".
    Wambaugh JF
    Environ Int; 2018 Dec; 121(Pt 2):1372-1374. PubMed ID: 30420130
    [No Abstract]   [Full Text] [Related]  

  • 90. Critical endpoints of PFOA and PFOS exposure for regulatory risk assessment in drinking water: Parameter choices impacting estimates of safe exposure levels.
    Perez A; Lumpkin M; Kornberg T; Schmidt A
    Regul Toxicol Pharmacol; 2023 Feb; 138():105323. PubMed ID: 36599390
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Data derived Extrapolation Factors for developmental toxicity: A preliminary research case study with perfluorooctanoate (PFOA).
    Dourson ML; Gadagbui B; Onyema C; McGinnis PM; York RG
    Regul Toxicol Pharmacol; 2019 Nov; 108():104446. PubMed ID: 31425727
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Weight of evidence evaluation for chemical-induced immunotoxicity for PFOA and PFOS: findings from an independent panel of experts.
    Garvey GJ; Anderson JK; Goodrum PE; Tyndall KH; Cox LA; Khatami M; Morales-Montor J; Schoeny RS; Seed JG; Tyagi RK; Kirman CR; Hays SM
    Crit Rev Toxicol; 2023 Jan; 53(1):34-51. PubMed ID: 37115714
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Bayesian Refinement of the Permeability-Limited Physiologically Based Pharmacokinetic Model for Perfluorooctanoic Acid in Male Rats.
    Cheng W; Ng CA
    Chem Res Toxicol; 2021 Nov; 34(11):2298-2308. PubMed ID: 34705448
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Perfluorohexanoic acid toxicity, part I: Development of a chronic human health toxicity value for use in risk assessment.
    Luz AL; Anderson JK; Goodrum P; Durda J
    Regul Toxicol Pharmacol; 2019 Apr; 103():41-55. PubMed ID: 30639337
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Comparing models for perfluorooctanoic acid pharmacokinetics using Bayesian analysis.
    Wambaugh JF; Barton HA; Setzer RW
    J Pharmacokinet Pharmacodyn; 2008 Dec; 35(6):683-712. PubMed ID: 19130186
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Prenatal Exposure to Perfluorooctane Sulfonate impairs Placental Angiogenesis and Induces Aberrant Expression of LncRNA Xist.
    Chen G; Xu LL; Huang YF; Wang Q; Wang BH; Yu ZH; Shi QM; Hong JW; Li J; Xu LC
    Biomed Environ Sci; 2018 Nov; 31(11):843-847. PubMed ID: 30558704
    [No Abstract]   [Full Text] [Related]  

  • 97. A straw man proposal for a quantitative definition of the RfD.
    Hattis D; Baird S; Goble R
    Drug Chem Toxicol; 2002 Nov; 25(4):403-36. PubMed ID: 12378950
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Mechanistic Middle-Out Physiologically Based Toxicokinetic Modeling of Transporter-Dependent Disposition of Perfluorooctanoic Acid in Humans.
    Lin J; Chin SY; Tan SPF; Koh HC; Cheong EJY; Chan ECY; Chan JCY
    Environ Sci Technol; 2023 May; 57(17):6825-6834. PubMed ID: 37072124
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Disposition of perfluorooctanoic acid in the rat after single and subchronic administration.
    Ylinen M; Kojo A; Hanhijärvi H; Peura P
    Bull Environ Contam Toxicol; 1990 Jan; 44(1):46-53. PubMed ID: 2306537
    [No Abstract]   [Full Text] [Related]  

  • 100. Probabilistic Points of Departure and Reference Doses for Characterizing Human Noncancer and Developmental/Reproductive Effects for 10,145 Chemicals.
    Aurisano N; Jolliet O; Chiu WA; Judson R; Jang S; Unnikrishnan A; Kosnik MB; Fantke P
    Environ Health Perspect; 2023 Mar; 131(3):37016. PubMed ID: 36989077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.